[HTML][HTML] PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging—a literature review
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …
[HTML][HTML] PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
G Planes-Laine, P Rochigneux, F Bertucci, AS Chrétien… - Cancers, 2019 - ncbi.nlm.nih.gov
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
G Planes-Laine, P Rochigneux, F Bertucci… - …, 2019 - search.proquest.com
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …
[PDF][PDF] PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
G Planes-Laine, P Rochigneux, F Bertucci, AS Chrétien… - pdfs.semanticscholar.org
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
G Planes-Laine, P Rochigneux, F Bertucci… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
G Planes-Laine, P Rochigneux, F Bertucci, AS Chrétien… - Cancers, 2019 - hal.science
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
R Planes-Laine, C Bertucci, S Viens - Cancers, 2019 - cir.nii.ac.jp
抄録< jats: p> Recently, the development of immunotherapy through the immune checkpoint
blockade led to long-lasting responses in several types of cancers that are refractory to …
blockade led to long-lasting responses in several types of cancers that are refractory to …
[PDF][PDF] PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
G Planes-Laine, P Rochigneux, F Bertucci, AS Chrétien… - partolab.com
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
G Planes-Laine, P Rochigneux, F Bertucci, AS Chrétien… - Cancers, 2019 - amu.hal.science
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review.
G Planes-Laine, P Rochigneux, F Bertucci… - …, 2019 - search.ebscohost.com
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …